[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Different Pharmaceutical Companies Examined by MP Advisors in Topical Reports Published at MarketPublishers.com

13 Nov 2013 • by Natalie Aster

LONDON – Market Publishers Ltd announces that topical MP Advisors reports on different pharmaceutical companies have been added to its catalogue.

CADILA HEALTHCARE , Lipaglyn Launched in India - Survey suggests quick market acceptance, if priced appropriately. Cadila Healthcare is an Indian pharmaceutical company with HQ in Ahmedabad. Recently, it has announced the launch of the new dual PPAR agonist Lipaglyn for diabetic dyslipidemia treatment. Lipaglyn is expected to earn approximately INR 650 million in peak sales in India by 2016. More information on the company’s operations are on hand in the study …

Generic Advair - 3 years to go, but which generic companies are better poised?. Recently, the USFDA announced the draft guidance for the development of Advair, generic version of GSK’s Asthma / COPD drug. The guidelines create favourable conditions for generic companies to launch a substitutable and interchangeable version of Advair in the US market. Mylan and Sandoz have good prospects for entering the market in 2016.  …

Amgen (AMGN) - Onyx Acquisition + Maturing Pipeline + Biosimilar Opportunity = Better Poised Than Large Pharma!.  Amgen (AMGN) has recently taken over Onyx pharma. This acquisition allowed the company to strengthen its Oncology/ Hematology drug portfolio by adding to it such Onyx’s marketed products as Kyprolis, Nexavar and Stivarga. Amgen has a co-promotion agreement with Bayer in the US for Nexavar and Stivarga …

MORPHOSYS (MOR) - MOR103/ MOR202 - Partnering is the Beginning of a New Phase of Growth. Alliances with GSK and Celgene in 2013 enabled MorphoSys (MOR) grow into a successful mature biotech company. Further, the company performance is expected to be boosted by licensing of un-partnered early programs and the clinical data of its maturing therapeutic antibody pipeline …

GSK - FDA Advisory committee positive on Anoro Ellipta - First once daily dual bronchodilator for US COPD patients. GSK together with Theravance have recently announced that the FDA pulmonary allergy Drugs Advisory Committee recommended in favor of approval of lower dose regiment (once per day). Anoro is likely to garner world peak sales of around USD 1.5 billion. More relevant information can bу found in the report …

More insightful market research studies by the publisher can be found at MP Advisors page.


The Market Publishers, Ltd.
Tanya Levdikova
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]

Analytics & News

Weekly Digest